Lymphocyte sensitization in childhood solid tumours and lymphoblastic leukaemia, measured by electrophoretic mobility test. by Lampert, F. et al.
Br. J. Cancer (1977) 35, 844.
LYMPHOCYTE SENSITIZATION IN CHILDHOOD SOLID
TUMOURS AND LYMPHOBLASTIC LEUKAEMIA, MEASURED
BY ELECTROPHORETIC MOBILITY TEST
F. LAMPERT, U. NITZSCHKE AND T. ZW-ERGEL
Frow the KiJnderpoliklinik, Justus Liebig-University, 6300 Giessen, TIt. Germany
Received 22 November 1976 Accepte( 14 February 1977
Summary.-A modified electrophoretic mobility (EM) test was performed in 150
children to examine their lymphocyte sensitization to myelin basic protein (encepha-
litogenic factor). Measurements in the cytopherometer were facilitated by using
devitalized sheep erythrocytes as indicator particles instead of macrophages. A
significant decrease in EM was found in 29/30 children with acute lymphoblastic
leukaemia and in 67/75 children with solid tumours, thus giving a false negative rate
in malignant disease of 9/105 = 8.6%, as compared to 6 false positives among 45
children with non-malignant disorders; 5 of the latter " false/positive " 6 patients
had autoimmune disease. Results of the EM test in the children with leukaemia were
compared withthosein9patientswithnon-Hodgkin'slymphomaand2 withHodgkin's
disease at different stages, but no striking change was seen between different
diseases, or after cessation of long-term immunosuppressive chemotherapy.
Percentage of " slowing " ranged from 4 to30o/. These results indicate that patients
with lymphoid malignancies still have lymphocytes which had been sensitized by a
common antigen of the malignant cell clone at the beginning of the disease. The
EM test, furthermore, could serve as an additional diagnostic aid in differentiating
benign from malignant masses in the abdomen, extremities or intracranial disease.
IN UTILIZING the macrophage electro-
phoretic mobility (MEM) test Field and
Caspary (1970) found that the peripheral
blood lymphocytes ofpatients with cancer
were sensitized to a basic protein derived
from human brain (encephalitogenic fac-
tor EF).
Subsequent reports confirmed the val-
iditv of the MEM test in distinguishing
between patients with benign and malig-
nant diseases (Pritchard et al., 1972;
Goldstone, Kerr and Irvine, 1973;
Irmscher et al., 1975; Shaw, Ettin and
McPherson, 1976).
The electrophoretic mobility (EM)
test was recently modified by replacing
guinea-pig macrophages by devitalized
sheep erythrocytes as indicator particles
ini the cytopherometer (Porzsolt, Tautz and
Ax, 1975). The modification made meas-
urements in the cvtopherometer easier
and more reliable.
The purpose of our investigation was
(1) to apply this modified EM test with
EF antigen to children with malignancies,
as childhood tumours are clinically and
cytologically different from adult cancer
disease, and (2) particularly, to test
lymphocytes of children with lympho-
blastic leukaemia and lymphoma in long-
term remission, where no EF sensitization
has been previously reported.
MATERIALS AND METHODS
Patients.-Peripheral blood was obtained
from 150 patients: 30 children Mwith acute
lymphoblastic leukemia (ALL) in haemato-
logical remission, 75 children with solid
tumours, and 45 children -with non-malignant
diseases. Twenty-five ofthe patients (10 with
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ALL + 15 with solid tumours) could be
studied at the Children's Hospital, University
of Munich, thanks to the generous help of
Drs R. J. Haas and R. Eife. Treatment of
the patients with ALL consisted of com-
bination chemotherapy for 2 to 3 years,
including prophylactic cranial irradiation,
leading to a 5-year leukaemia-free survival of
30-50% (Pinkel, 1976).
Lymphocyte isolation.-Fifteen to 20 ml of
heparinized whole blood (LiqueminS Roche
500 i.u./10 ml) wasdilutedwithequalamounts
of Hanks's solution (Flow Laboratories) con-
taining 0.005% EDTA (Merck) and layered
over Triosil-Ficoll® in sterile 80-ml glass
centrifuge tubes. The lymphocyte-enriched
interface was recovered after centrifugation
(400 g, 30 min) and washed once in Hanks's
solution with 0.005% EDTA (400 g, 15 min).
The cells were then transferred into sterile
polypropylene tubes, washed twice in Hanks's
balanced salt solution andresuspended in 1 ml
ofDulbecco's medium to a final concentration
of 104 cells/,ul.
Antigen preparation.-The encephalito-
genic factor (EF, kindly supplied by Prof.
Ax, Behringwerke, Marburg) was prepared
as crude EFprotein from normal human brain
as described by Dickinson, Caspary and Field
(1973).
Incubation procedures.-Incubations with
antigen and indicator particles were per-
formed according to Porzsolt et al. (1975):
0-7 ml of the lymphocyte suspension was
incubated with 3-0 ml of EF solution (0 3 mg
EF/ml Hanks's balanced salt solution, HBSS)
for 4 h at 37°C. The cells were then spun at
800 g for 15 min, and 3 ml ofthe supernatant
was pipetted offfor either immediate process-
ing or storage at -20°C. After thawing, 3 ml
of the supernatant was incubated with 1 ml
of a suspension oftanned and sulphosalicylic-
acid-stabilized sheep erythrocytes (ETS,
kindly supplied by Prof. Ax, Behringwerke,
Marburg) (5 x 107 ETS/ml HBSS) for 90 min
at 2300. As a control, supernatant without
EF was prepared for each test, 1 ml ETS
(5 x 107 ETS/ml HBSS) was incubated with
3 ml of a mixture of Dulbecco's medium and
HBSS (7 : 30) for 90 min at 23°C in a water
bath.
Cytopherometer.-Measurements of ETS-
electrophoretic mobility were performed in a
Zeiss cytopherometer, using a current of6 mA
at l10 V, and maintaining the observation
chamber at a temperature of 230°C. All
samples were presented for blind measure-
ments in random order.
Measurements and calculations.-For each
incubation mixture, 20 erythrocytes were
timed with two stopwatches across the given
distance of 16 ,um in the ocular eye-piece in
both directions of the potential difference.
To prevent timing errors by cell drifting,
actual migration time was expressed by the
formula t = 2a(b-a)/b (Porzsolt et al., 1975)
in which t is the actual migration time, a the
migration time in one direction, and b the
total migration time in both directions. For
each specimen, the mean actual migration
time of 20 ETS indicator particles ± the
standard deviation was determined inrelation
to the control which was freshly prepared for
each day that measurements were made.
The % reduction in mobility was calculated
according to the formula:
% slowing-
mean of test sample-mean of control X 100
mean of control
The results, i.e. increased or decreased
mobility, were always tested for statistical
significance (Student's t test) in relation to the
control; " Positive " results ( + ) indicate
a significant decrease in mobility as compared
to the control; " negative " results ( -)
either are not significantly different to the
control or show a significant increase in
mobility.
Two controls were alwaysfreshlyprepared
for each day of measuring. This reference
was necessary as the ETS indicator particles,
depending on age or different donor sheep,
showed variations in mobility. The timing of
all controls was 4-3 + 0-6 s (mean + s.d.).
RESULTS
A scattergram showing the pooled
results of 150 children with different
malignant and non-malignant disorders is
presented in Fig. 1. The data of the
3 groups of Fig. 1 were statistically
examined by the Scheffe test. The differ-
ences between the group ofnon-malignant
disorders (with or without autoimmune
disease) and the groups of malignant
tumours and acute lymphoblastic leuk-
aemia were highly significant (P < 0 001).
No significant difference was seen between
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FIG. Results of electirophoretic mobility (EMI)
test o)l 1 50 childreni.
the groups of acute lymphoblastic leuk-
aemia and malignant solid tumours. In
comparing the results in relation to the
control, there were 67/75 children with
tumours and 29/30 children with acute
lymphoblastic leukaemia (all in haemato-
logical remission) who responded to lym-
phocyte stimulation by EF antigen, i.e.
mobility inhibition. This gives a tot,al of
9/105 8.600 false negatives, or a canicer
sensitivity of over 900). In cointrast,
almost, all 45 children with non-malignant
diseases had either significant ' negative
slowing" or no significant, " positive slow-
ing ". Five of 6 false positive results were
children with autoimmune disorders (onie
with rheumatoid arthritis, one with ulcera-
tive colitis, 2 with Crohn's disease, one
with dermatomyositis). The other pa-
tients in the group of non-malignant
diseases had haematological, renal or
metabolic disorders, or acute infections.
The meaning of increased mobility in
these patients remains obscure. Patients
with lymphoblastic leukaemia and lvm-
phoma in different stages of their disease
were compared in Table I. Only one child
with ALL still in remission had a " nega-
tive slowing ". All the others had a
significant slowing relative to the control,
ranging from 4 to 288%. No real major
difference was seen either between the
different, lymphoid malignanciesl or be-
tween " on " and " off" therapy. " Off
therapy patients" had a slowing iin t,he
range of9to 2100, "ontherapy patients " a,
similar range of slowing (10 to 280o). NoIn-
Hodgkin's lymphoma patients under treat-
ment had a slowing ranging from 7 to 300/' .
TABLE I. EM Test in Children with Acute Lymphoblastic Leukaernia (ALL),
Hodgkin's Disease (HD) and N'on-Hodgkin's Lymphoma (X79HL)
Decreasedi ( T4) oi1
Increase(d (-)
Mobility
Diagnosis, current status
ALL complete remissioin, off therapy
ALL complete remission, on therapy
ALL 2 months aftei (diagnSosis
ALL 2- years aftei (liagnosis
lD, Stage IIA in complete remissioin, offtherapy
IHD, Stage IIB in complete remission, oni therapx
NHL conrtinuous complete remission, offtherapy
NHL complete remission, on therapy
No. of
patielits
a
4
17
1
1
1
1
:3
3s
No. of tests
per patient
4
4
I 2
2
1
1
4
4
2
]
3s
Range
from to
11- 3 - 16 -1
7 7-4 -210
7-1 +27 9
9-3 +18-7
9. 1 9.4
2-2-
4-2 + 4-7
- 5-0 +22 1
81 2-5 -25
+10-8 30:3
10-4 +13 -1
5-0 +16 -9
Aleal
+ 1C3 -4
-1 7 -
7.*4
+~4 -;)
X 10 2
-- 15-1
15-1
846
;-;--
* *-
4
1
:44
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Results of the EM test in children
with solid tumours of the abdomen and
extrenmities in different stages of their
diseases, are summarized in Table II.
Only 1/26 patients, a 9-year-old boy
whose adrenal neuroblastoma was re-
moved 5 years earlier, had a " negative
slowing ". No difference was seen be-
tween patients with tumour (e.g. before
operation) or tumour-free. Greatest slow-
ing was produced by lymphocytes of an
11-year-old girl with malignant teratoma
(teratoid chorionepithelioma) which had
been removed 6 years earlier.
EM testing in children with intracran-
ial disease (Table III) could clearly dis-
tinguish between cerebellar medulloblast-
oma, astrocytoma and brainstem tumour,
giving a, positive slowing ", from epilepsy
and aseptic meningitis with " negative
slowing ". Range of the 4 patients with
ependy,moma was from a negative slowing
of -90 to a positive slowing of over
+ 200o. One patient with old excised
craniopharyngeoma and diabetes insipidus
was strikingly negative ( 10%).
DISCUSSION
Among in vitro tests to detect lympho-
cyte sensitization against tumour-associa-
ted antigens (e.g. cytotoxicity techniques,
macrophage migration inhibition, leu-
cocyte adherence inhibition), the MEMI
test is credited with the greatest sensi-
tivity. Immunological specificity, how-
ever, is somewhat limited, in that not onlv
patients with malignant diseases but also
those with autoimmune disorders, as well
as with demyelinating disease, give a
positive reaction to myelin basic protein
or tumour basic protein as antigen.
Universal acceptance of the MEM test
as a test for cancer was also hampered
by the difficult performance of the cyto-
pherometer recordings.
Most of the technical difficulties of the
MEM test, however, can be attributed to
the guinea-pig macrophages as indicator
cells. These problems have now been
overcome by the modification which we
adopted from Porzsolt et al (1975) of
using tanned and sulphosalicylic-acid-
stabilized sheep erythrocytes (ETS) in-
stead of peritoneal macrophages. These
erythrocytes represent a uniform popula-
tion in size and migration, can be obtained
in large quantities as a standardized com-
mercial product (Tanned and Sulpho-
salicylic-acid-stabilized Sheep Erythro-
cytes, ETS, Behringwerke, Marburg, W.
TABLE II. EM Test in Children with Malignant Tumours of the Abdomen
and Extremities
Diagnosis, current status
Neuroblastoma, with tumour
Neuroblastoma, tumour remove(l
Neuroblastoma, no tumour for 5 years
Wilm's ttumouir, with tumour
Wilm's tuimouir, tumour remove(d
Rhabdomyosarcoma
Ostoosarcoma, after amputation
Ewing's sarcoma
Chondrosarcoma, with tumour
Malignant teratoma, tumouir removed
No. of
patients
1
3
1
1 1
2
1
3
1)
1
No.
per I
of tests
patient
Decreased (--) or
Increased (-)
Mobilitv
Raiige
from to AIean
1 I-9 2
2 -'13 7 -22 1
3 58 25 + 13 6
1 9 6
2 1.9 - 0 9
1 + 16 1
4 7 7 8 + 16 5
1 11 .:11 + 19 8
2 13 8 14.4
4 + 12 6 +23O0
1 + 14-0 21-0
5 *4 -8 7
1 + 15 8
12-4 r15 2
3 + 5 6 12' 8
2 + 5 8 12 2
3 25 8 + 31 7
+ 14 5
- 1 4
+ 13 2
+-14 4
+ 12 7
4- 7 9
+ 9*8
- 6.1
+ 28 3
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TABLE III.-EMTest in Children with Different Intracranial Diseases
Diagnosis
Medulloblastoma
Astrocytoma
Ependymoma
Brain-stem tumour
Aseptic meningitis, tumour?
Seizures, strange behaviour, tumour?
Encephalitis
Craniopharyngioma
Epilepsy
Asceptic meningitis
Meningococcal meningitis
Dizziness, hypotension
Decerebration
Cerebral contusion
Decreased (+) or
Increased (-)
Mobility
Range
No. of No. of tests , A
patients per patient from to Mean
3
1
2
1
2
1
1
1
1
1
1
1
4
2
1
4
1
1
1
1
1
Germany) and remain stable for a long
period of time. As to the antigen, we
used encephalitogenic factor because the
preparation is standardized and the pro-
duct commercially available and, further-
more, there is cross-reactivity with myelin
basic protein and tumour basic protein.
Other important points of our method are
to have a sufficient amount of patient's
lymphocytes (107/ml) and an incubation
time withantigen of4 h.
Our results confirm the high sensitivity
of the EM test in malignant disease, with
less than 10% false negatives. This
reflects the embryonal, undifferentiated
nature ofmalignancy in childhood. Speci-
ficity was limited by 13% false positives
if patients with autoimmune disease such
as ulcerative colitis, Crohn's disease and
dermatomyositis were included. In clin-
ical routine we found the EM test helpful
in establishing the diagnosis before opera-
tion, in several patients with a mass in the
abdomen. As to leukaemia, there were
only sparse reports of MEM testing in the
literature. Field, Caspary and Smith
(1973) examined adults with leukaemia
1 + 8-6 +11-6
2 + 5.5 + 5-7
2 +10-0 +28-9
1 +19-1
2 - 8-7 +14-8
4 + 2-8 +22-8
1 +9-5
2 + 7-9 + 8-6
1 +9-6
1 +6-1
1 +1-1
2 -10-9 - 9-3
1 - 4'6 - 0-1
2 - 6-4 - 4-2
3 -19-6 -15-3
1 - 8-8 - 1-2
2 - 4-7 - 2-0
2 - 4-2 - 3-6
2 - 4-6 - 3.9
2 - 3-2 - 1-3
2 -12-7 - 3-0
+ 8-5
-+19-3
+ 8-3
+ 8-3
-10-1
- 7-9
- 4-3
- 3-9
- 4-3
- 2-3
- 7-9
and found no reactivity, probably due to
theleukaemic nature ofthe testedlympho-
cytes. In children, the situation of
leukaemia nowadays is completely differ-
ent to that of adults. Thanks to modern
combination chemotherapy, up to 50% of
children with lymphoblastic leukaemia
can now enjoy relapse-free survival of
5 years and longer. These children repre-
sent a uniform population as to disease,
treatment and prognosis. We examined
the lymphocytes of these patients in
haematological remission and found, (1) a
strong reactivity to encephalitogenic fac-
tor, (2) no major difference from patients
with lymphoma, and (3) no major differ-
ence between patients " on " and " off "
therapy.
Thus the presence of a common,
unspecific antigen in lymphoblastic leuk-
aemia and lymphoma cells finds further
support.
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